Effects of dapagliflozin on renal function in heart transplant recipients.

19 May 2025 (10:36 - 12:12)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Miss Aleksandra Gutowska

University Clinical Centre UCK, Gdansk (Poland)

4 More presentations in this session

Presentation thumbnail

Histopathologic insights into AVF functionality and heart failure in end-stage renal disease

Mrs V. Samsone (Vilnius, LT)

Abstract Slides Video

Presentation thumbnail

Chemotherapy versus tumour burden: evaluating their roles in cardiovascular risk enhancement for breast cancer patients

Doctor R. Fernandes (Coimbra, PT)

Abstract Slides Video

Presentation thumbnail

Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials

Doctor J. Ostrominski (Boston, US)

Abstract Slides

Presentation thumbnail

Exploring the hemoglobin-cardiovascular link in chronic kidney disease patients

Doctor T. Pereira dos Santos (Coimbra, PT)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in cardiovascular disease in special populations (3)

The Event

Event poster

Heart Failure 2025

19 May 2025 10:36 CET

You may be interested in

Congress Presentation

Microalbuminuria in heart transplant recipients -insights from the randomized trial dapagliflozin for renal protection in heart transplant recipients (DAPARHT)

Congress Presentation

Baseline characteristics of the first one hundred and two patients enrolled in the trial DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT)

Congress Presentation

Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources